CTI Clinical Trial and Consulting Services Announces the Formation of a United Kingdom Affiliate and Opening of London Office
CTI Clinical Trial and Consulting Services (CTI) announces the formation of a new United Kingdom affiliate, CTI Clinical Trial and Consulting Services UK Ltd., and the opening of an office outside of London, England.
“The new company and UK location allows CTI to continue to better serve the growing base of global pharmaceutical and biotechnology companies throughout Western Europe,” states Patrick Earley, General Manager at CTI. “Additionally, the UK pharmaceutical and biotechnology industry is extremely important to medical research as a whole, and UK medical centers perform a great deal of research in the critically ill patient population that CTI excels at, so this is a great opportunity.”
CTI has been working for more than a decade in the drug development industry in North America, Europe, and South America, specializing in clinical research programs involving critically ill patient populations.
About CTI Clinical Trial and Consulting Services
CTI is a specialty drug and market development company offering a full range of services that encompass the entire lifecycle of drug development. These services include regulatory pathway design, clinical trial management, data analysis, medical writing, CME and training program development, market analysis and development and other consulting services. CTI focuses on critically and chronically ill patient populations in the specific disease areas of solid organ transplant, hepatitis, infectious disease, hematology/bone marrow transplant and end-stage organ disease including cardiovascular disease, liver disease and kidney disease. With its combined expertise of clinical knowledge and market experience, CTI is uniquely positioned to incorporate both clinical and market driven endpoints and interpretations to provide results.
CTI is headquartered in Cincinnati, Ohio with locations in North America, Europe, and South America. They were recognized by the Cincinnati Business Courier as a “Best Place to Work” in Greater Cincinnati for 2008 and 2009 and were named a “Top Work Place” by the Cincinnati Enquirer in 2010.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
